De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

aTyr Pharma Toekomstige groei

Future criteriumcontroles 5/6

De verwachting is dat aTyr Pharma de winst en omzet met respectievelijk 67.4% en 71.7% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 67.3% per jaar.

Belangrijke informatie

65.7%

Groei van de winst

66.0%

Groei van de winst per aandeel

Biotechs winstgroei	35.0%
Inkomstengroei	73.6%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	09 Oct 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

DB:471A - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	64	-38	-65	-111	7
12/31/2025	5	-64	-57	-64	7
12/31/2024	0	-65	-58	-67	7
6/30/2024	1	-58	-64	-63	N/A
3/31/2024	1	-54	-58	-55	N/A
12/31/2023	0	-50	-37	-33	N/A
9/30/2023	11	-43	-38	-33	N/A
6/30/2023	10	-45	-40	-35	N/A
3/31/2023	10	-45	-35	-32	N/A
12/31/2022	10	-45	-44	-42	N/A
9/30/2022	N/A	-46	-40	-40	N/A
6/30/2022	N/A	-41	-39	-39	N/A
3/31/2022	N/A	-39	-38	-37	N/A
12/31/2021	N/A	-34	-33	-33	N/A
9/30/2021	2	-30	-31	-30	N/A
6/30/2021	2	-29	-25	-24	N/A
3/31/2021	2	-25	-23	-23	N/A
12/31/2020	10	-16	-16	-15	N/A
9/30/2020	9	-17	-15	-15	N/A
6/30/2020	9	-16	-14	-14	N/A
3/31/2020	8	-16	-12	-12	N/A
12/31/2019	0	-24	-20	-20	N/A
9/30/2019	0	-24	-20	-20	N/A
6/30/2019	0	-25	-22	-22	N/A
3/31/2019	N/A	-30	-27	-27	N/A
12/31/2018	N/A	-35	-32	-31	N/A
9/30/2018	N/A	-40	-37	-37	N/A
6/30/2018	N/A	-44	-40	-39	N/A
3/31/2018	N/A	-45	N/A	-39	N/A
12/31/2017	N/A	-48	N/A	-42	N/A
9/30/2017	N/A	-49	N/A	-44	N/A
6/30/2017	N/A	-52	N/A	-50	N/A
3/31/2017	N/A	-55	N/A	-54	N/A
12/31/2016	N/A	-58	N/A	-53	N/A
9/30/2016	N/A	-62	N/A	-51	N/A
6/30/2016	N/A	-59	N/A	-46	N/A
3/31/2016	N/A	-55	N/A	-43	N/A
12/31/2015	N/A	-48	N/A	-37	N/A
9/30/2015	N/A	-38	N/A	-33	N/A
6/30/2015	N/A	-33	N/A	-29	N/A
3/31/2015	N/A	-28	N/A	-23	N/A
12/31/2014	N/A	-25	N/A	-23	N/A
9/30/2014	N/A	-24	N/A	-21	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat 471A de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 0.8% ).

Winst versus markt: Er wordt verwacht dat 471A de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat 471A binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van 471A ( 71.7% per jaar) zal naar verwachting sneller groeien dan de markt German ( 5.4% per jaar).

Hoge groei-inkomsten: De omzet van 471A ( 71.7% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van 471A naar verwachting over 3 jaar hoog zal zijn

aTyr Pharma Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Forecast to breakeven in 2026

Recent updates

Independent Director recently bought €170k worth of stock

aTyr Pharma, Inc. Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

Independent Chairman of the Board recently bought €81k worth of stock

aTyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma, Inc., Annual General Meeting, May 22, 2024

New major risk - Share price stability

New major risk - Revenue size

Forecast to breakeven in 2026

aTyr Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024

aTyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis

Atyr Pharma, Inc. Announces Dosing of First Patient in Phase 2 Efzo-Connect™? Study of Efzofitimod in Patients with Ssc-Ild

Atyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, Fvc and Patient Reported Outcomes

Independent Director recently bought €410k worth of stock

Insufficient new directors

aTyr Pharma, Inc. Announces Publication of Positive Data from Phase 1B/2A Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal Chest

aTyr Pharma, Inc. to Report Q3, 2022 Results on Nov 10, 2022

aTyr Pharma, Inc. Announces Dosing of First Patient in Pivotal Phase 3 Efzo-Fit™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

aTyr Pharma, Inc. Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis

aTyr Pharma, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Atyr Pharma, Inc. Announces Phase 3 Study Evaluating the Efficacy and Safety of Its Lead Therapeutic Candidate, efzofitimod

aTyr Pharma, Inc. to Report Q1, 2022 Results on May 09, 2022

Insufficient new directors

aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

aTyr Pharma, Inc. Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name

Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.68 loss in 3Q 2020)

aTyr Pharma, Inc. Announces Positive Data from Phase 1B/2A Clinical Trial Demonstrating Consistent Dose Response for Atyr1923 in Pulmonary Sarcoidosis

Independent Director recently bought €163k worth of stock

Full year 2020 earnings released: US$1.77 loss per share (vs US$7.03 loss in FY 2019)

aTyr Pharma, Inc. to Report Q4, 2020 Results on Mar 23, 2021

aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications

Leading Cancer Researcher Dr. Judith Varner Joins aTyr Pharma as Scientific Advisor

aTyr Pharma Announces New tRNA Synthetase Discovery Programs

New 90-day high: €6.35

aTyr Pharma, Inc. Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

aTyr Pharma, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis

aTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline

aTyr Pharma, Inc. to Report Q3, 2020 Results on Nov 12, 2020

aTyr Pharma, Inc. Announces Completion of Enrollment in Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

aTyr Pharma, Inc. announced that it expects to receive $20 million in funding from Aspire Capital Partners, LLC

aTyr Pharma, Inc. to Report Q2, 2020 Results on Aug 13, 2020

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven